Clinical Trial Update: Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 imaging trial evaluating 89Zr-Trastuzumab in HER2-positive metastatic breast cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 89Zr-trastuzumab (zirconium-89-labeled trastuzumab)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Neoplasms, Secondary | Phase 1 | Status: COMPLETED | Results posted: 2017-04-18